RESUMO
BACKGROUND: (Meth)acrylates are potent sensitizers and a common cause of allergic contact dermatitis (ACD). The frequency of (meth)acrylate ACD has increased with soaring demand for acrylic nails. A preliminary audit has suggested a significant rate of positive patch tests to (meth)acrylates using aimed testing in patients providing a clear history of exposure. To date, (meth)acrylates have not been routinely tested in the baseline patch test series in the U.K. and Europe. OBJECTIVES: To determine whether inclusion of 2-hydroxyethyl methacrylate (2-HEMA) 2% in petrolatum (pet.) in the baseline series detects cases of treatable (meth)acrylate ACD. METHODS: During 2016-2017, 15 U.K. dermatology centres included 2-HEMA in the extended baseline patch test series. Patients with a history of (meth)acrylate exposure, or who tested positive to 2-HEMA, were selectively tested with a short series of eight (meth)acrylate allergens. RESULTS: In total 5920 patients were consecutively patch tested with the baseline series, of whom 669 were also tested with the (meth)acrylate series. Overall, 102 of 5920 (1·7%) tested positive to 2-HEMA and 140 (2·4%) to at least one (meth)acrylate. Had 2-HEMA been excluded from the baseline series, (meth)acrylate allergy would have been missed in 36 of 5920 (0·6% of all patients). The top (meth)acrylates eliciting a positive reaction were 2-HEMA (n = 102, 1·7%), 2-hydroxypropyl methacrylate (n = 61, 1·0%) and 2-hydroxyethyl acrylate (n = 57, 1·0%). CONCLUSIONS: We recommend that 2-HEMA 2% pet. be added to the British baseline patch test series. We also suggest a standardized short (meth)acrylate series, which is likely to detect most cases of (meth)acrylate allergy.
Assuntos
Acrilatos/imunologia , Alérgenos/imunologia , Dermatite Alérgica de Contato/diagnóstico , Metacrilatos/efeitos adversos , Testes do Emplastro/métodos , Adolescente , Adulto , Idoso , Cosméticos/efeitos adversos , Cosméticos/química , Dermatite Alérgica de Contato/epidemiologia , Dermatite Alérgica de Contato/imunologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Unhas , Estudos Prospectivos , Reino Unido/epidemiologia , Adulto JovemAssuntos
Dermatite Alérgica de Contato/patologia , Dermatoses Faciais/patologia , Neoplasias Faciais/patologia , Linfoma Anaplásico de Células Grandes/patologia , Neoplasias Cutâneas/patologia , Diagnóstico Diferencial , Neoplasias Faciais/tratamento farmacológico , Feminino , Humanos , Linfoma Anaplásico de Células Grandes/tratamento farmacológico , Pessoa de Meia-Idade , Neoplasias Cutâneas/tratamento farmacológicoRESUMO
Female pattern hair loss, also known as female androgenetic alopecia, is generally regarded as an androgen-dependent disorder representing the female counterpart of male balding. We describe female pattern hair loss occurring in a patient with complete androgen insensitivity syndrome suggesting that mechanisms other than direct androgen action contribute to this common form of hair loss in women.